Key facts
- Probius’s last known valuation is $25.0M (Dec 2020).
- It has raised $12.9M; the latest was Later Stage VC ($2.4M) in Aug 2025.
- Notable investors include Plug and Play Tech Center, Creative Destruction Lab, United States Department of War, StartX (US), Joyance Partners — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Probius
- ·The full record, as it builds
Funding rounds
No funding rounds for Probius are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Probius
Developer of an electronic sensing platform designed to offer broad-spectrum and point-of-care diagnostic services. The company's platform analyzes multiple target proteins in real-time and can be used for blood-draw quality checks and broad screening panels during emergency care settings, enabling doctors to deliver appropriate therapy within clinical settings to patients in need of critical care.
- Sector
- Healthcare
- HQ
- Fremont, CA, United States
- Founded
- 2015
- Employees
- 14
- Website
- probius.bio/
- Ownership
- Privately Held (backing)
Probius doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Probius shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Probius in its N-PORT filings yet. We sweep new filings monthly.